Dynamic 18F-FET and 18F-FDOPA acquisitions have recently shown encouraging predictive performances for the noninvasive characterization of the mutation status of isocitrate dehydrogenase (IDH) in newly diagnosed gliomas (6, 8). This evidence concerns the gene IDH3A and central nervous system cancer.